Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Brii Biosciences Limited ( (HK:2137) ).
Brii Biosciences Limited announced the grant of 600,000 share options to a service provider under its 2023 Share Option Scheme. This move is part of the company’s strategic initiatives to enhance its operational capabilities and retain key advisory services, potentially impacting its market positioning by aligning interests with stakeholders.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biotechnology company focused on developing innovative therapies for infectious diseases. The company operates in the biopharmaceutical industry, providing scientific and strategic advisory services.
Average Trading Volume: 7,002,246
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.36B
Learn more about 2137 stock on TipRanks’ Stock Analysis page.